Zymeworks 8/7/2025 Earnings Report

Zymeworks EPS Results

• Actual EPS: $0.03
• Consensus EPS: -$0.52
• Beat/Miss: Beat by +$0.55
• One Year Ago EPS: N/A

Zymeworks Revenue Results

• Actual Revenue: $48.73 million
• Expected Revenue: $13.66 million
• Beat/Miss: Beat by +$35.07 million
• YoY Revenue Growth: N/A

Zymeworks Announcement Details

• Date: 8/7/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Zymeworks (NASDAQ:ZYME), a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.